Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You are a minimalist alright lol.
I promise you, I do not need your assistance.
Perhaps only in how to be uber POMPOUS!
Can you outline these expectations, not sure to find them in the thread.
Thank you for the response, we will see what the company delivers this time around.
Maybe clarification on this is needed:
Really and what is my current analysis and future expectations?
Would love to hear lol.
Oh and by the way notice how the poster Investor, refuses to outline what a proper read out will be.
Since it can then be verified and graded.
What is idiotic about asking for the poster's expectations of a proper trial readout, so we can then compare and grade?
I simply asked if you were asking on his behalf, since the poster refuses to respond to a simple question.
I do not have PMs nor want to purchase the feature, nor want to wait till Friday.
I want a simple public answer for everyone to see what a SMART Investor, expects and considers a proper read out.
Sure Bob, just notice the silence.
Since I'm pretty sure my question was directed towards investor.
Do you speak on his behalf?
Let's see, maybe I get an outline of his expectations.
Otherwise, is just another revealing act of silence.
The purpose of my exercise is to gauge what a very very SMART investor expects from the company vs what the company delivers on its next clinical trial results, Rett in this case.
Then what the additional P2b/p3 AD FULL DATASET will deliver.
Will a negative view persist if the boxes check out?
Or are the negative views consistent with expectations vs reality.
Again I ask, what is YOUr SUBJECTIVE view of what these next clinical results should include?
I cant infer what you are thinking, not like you apparently can.
Because I want to hold you accountable to your word, I do not know the answer to this question?
Which by the way is subjective, and WHY I ask.
Oh and nice ad hominem attack LOL.
Can you spell out what a complete news announcement is to you?
This way we can compare after the fact, if it met the expectations.
That`s fair no?
Going down, but still at 25% NICE!
Please do let us know when it actually goes down lol.
LOL you are too much !!!
Yea his actually sounded better.
But this guy has 40 years of experience vs 30
This is exactly my same theory.
Speaking of NDA did you get the hint?
ofcourse you "didn't", but I did.
YOU seem to be missing my point.
All good my point doesn't need your approval
Double negative? Lol SMART!
I understand what you are saying, but you didnt answer my question to your question.
Clearly Anavex is not in the same situation.
It is clear that your point is that a CEO can say anything he wants and reality can say something else.
It is my point that our CEO has data to back up what he is saying.
Cmon now you are SMARTER than this.
Yes by logic and definition Anavex has better results thank you for bringing that up!
The more reason why Anavex is a ahead of the pack.
Or even better imagine if APOE4 patients were part of the strong responders, and our drug really does its job even on those high risk patients.
Of course you would suspect the APOE3 gene, since is apparently your job to do so.
This institution of 1 bought more shares today, unrelated to yesterdays news.
But good luck to them also.
I probably bought Leo`s shares since he was looking to exit around this price range.
Shrug.
Yea never been in the camp of AVXL being bought out by any BP.
I do however agree a partnership is possible, even with Roche despite their cash balance sheet.
I BELIEVE, you killed two birds with one stone.
hehe haha
Certainly not considering that not all deals are done via cash only.
Stock exchanges are also typical.
hehe haha
Dont forget cash is not the only way deals are made.
Stock can be involved as well.
I agree with this, nor its release time frame, so not sure why you keep pocking at it.
I mean rhetorically not sure
I hear you but imagine being Roche size and having ALL your resources focused on one acquisition?
Never mentioned the cabal nor care about the share price, I mentioned some pretty remarkable results dont you agree?
Maybe you might need to consult with the local grammar teacher on this sentence structure.
My mistake if you are alluring to AA in AD being filed, then peer review coming out which would then reinforce or weaken the results, from an investors view and decision making.
Granted, English is not my forte, however looking for spins is.
I agree, it is laughable.
Just look at what he tried doing yesterday with SAVA.
I do not have an investment there.
But my oh my, he went out of his way to mention how NOBODY (except him) was talking about their drug on CTAD, just because they were up 20% on the day lol.
Talk about sending the dog out when scared lol.
It all depends when he bought.
Also it doesnt matter, have you ever seen glioblastoma of the brain survival patients like the ones in NWBO?
The results were published in a peer-reviewed cancer journal, JAMA Oncology12. The publication was co-authored by more than 70 physicians from leading institutions across the U.S., Canada, U.K., and Germany
Or are you in the AF camp that these "Doctors" are just miss guided lol.
When approved, it will be irrelevant buying at 1.04(recent high) or .40 (recent low).
So you really believe Anavex is waiting for the peer review to apply for AA LMAO.
Nice try, but Im not in that camp.
I'm in the camp that they are meeting with regulatory agencies in parallel as a peer review last time I checked was not an NDA requirement.
6-10 years, that soon? dam ill be in my early 40s if luck permits, not bad not bad at all.
He clearly doesn't care what experts in the field have to say.
He sees himself and his political science major above the medical and scientific field.
Look at what he did with NWBO, which has brain cancer patients surviving after 5 years in a terminal type of cancer.
Drs in the field have spoken about it this breakthrough on journal paper.
All he has to say is these doctors mean well but he knows better, NWBO failed its trial according to him.
Again!
Even tho they have survivors in a disease that is terminal AND professionals agreeing it is a never before seen break through.
He is in the spin business not the fact one.
So? What difference does it make?
Again missing the forest for the trees.
FULL AD DATASET, which was argued here was not going to be released by some here, wink wink.
WILL be released in a JOURNAL.
This year or next, who cares the year is over in less than 2 months.
BUT RETT will be THIS year not FEBISH.
So thank you Dr.M for the update.
He suffers from selective reading comprehension.
I suspect.
YOU!! are missing the forest for the trees.
The beef of the PR in my opinion is this:
We also look forward to presenting in an upcoming major publication the complete dataset of the Phase 2b/3 Alzheimer’s disease trial of ANAVEX®2-73 (blarcamesine), a potential next-generation precision medicine convenient once daily oral Alzheimer’s disease treatment,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. "We are also on track within our neurodevelopmental precision medicine Rett syndrome program to release top-line data of ANAVEX®2-73-RS-003 Phase 2/3 EXCELLENCE pediatric clinical trial in the current quarter of 2023.”
3-71 was just the vehicle of delivery!
This is the beef.